5‐Heptadecylresorcinol ameliorates high‐fat diet induced non‐alcoholic fatty liver disease through modulating bile acid profile and suppressing inflammation
Journal of the Science of Food and Agriculture · 2025
DOI: 10.1002/jsfa.70060 ↗At a glance
Journal article in Journal of the Science of Food and Agriculture, 2025. Written by Zihui Yang and 7 co-authors. Institution: Key Laboratory of Geriatric Nutrition and Health (Beijing Technology and Business University), Ministry of Education, Beijing, China. Major MEDLINE topics: Non-alcoholic Fatty Liver Disease, Resorcinols, Bile Acids and Salts. Cited 1 times so far (Crossref); 46 references. Funded by: National Natural Science Foundation of China (32172207), Beijing Nova Program (20230484307), Project of Cultivation for young topnotch Talents of Beijing Municipal Institutions (BPHR202203041).
Abstract (original language)
BACKGROUND The risk of non‐alcoholic fatty liver disease (NAFLD) has been inversely associated with whole grain consumption. 5‐Heptadecylresorcinol (AR‐C17) is a phenolic lipid present in the bran part of whole grain wheat, which has been proven to ameliorate obesity and atherosclerosis. However, whether AR‐C17 could alleviate NAFLD and the underlying molecular mechanisms remain unclear. RESULTS AR‐C17 administration (150 mg/kg) significantly attenuated high‐fat diet (HFD)‐induced NAFLD in mice by reducing serum total cholesterol (TC), low‐density lipoprotein cholesterol (LDL‐C), and aspartate aminotransferase (AST) levels, accompanied by significant improvements in hepatic steatosis, inflammation, and fibrosis. Accordingly, serum metabolomics revealed distinct clustering of different treatment groups, and the pathway enrichment analyses indicated that AR‐C17 could significantly modulate primary bile acid biosynthesis. Hepatic target metabolomics further confirmed that AR‐C17 administration profoundly altered bile acid profiles. Western‐blot analysis showed that AR‐C17 treatment up‐regulated FXR (farnesoid X receptor) expression and inhibited the activation of NLRP3 (nucleotide‐binding oligomerization domain‐like receptor with a pyrin domain 3) inflammasome. CONCLUSION AR‐C17 mitigated the progression of NAFLD by modulating the hepatic bile acid profile and reducing systemic inflammation through FXR signaling pathway. © 2025 Society of Chemical Industry.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Key Laboratory of Geriatric Nutrition and Health (Beijing Technology and Business University), Ministry of Education, Beijing, China.
- Aviation Health Assurance and Flight Safety Research Laboratory, Air Force Medical Center, Air Force Medical University, Beijing, China.
- National Center of Technology Innovation for Grain Industry (Comprehensive Utilization of Edible By-products), Beijing Technology and Business University, Beijing, China.
ORCID profiles: Ziyuan Wang, Jing Wang, Jie Liu
Funding
- National Natural Science Foundation of China (32172207)
- Beijing Nova Program (20230484307)
- Project of Cultivation for young topnotch Talents of Beijing Municipal Institutions (BPHR202203041)
- Youth Talent Program of National Food and Strategic Reserves (QN2024403)
Cite
APA
Yang, Z., Hao, Y., Wang, Z., Wang, Z., Ye, G., Gao, F., Wang, J., & Liu, J. (2025). 5‐Heptadecylresorcinol ameliorates high‐fat diet induced non‐alcoholic fatty liver disease through modulating bile acid profile and suppressing inflammation. Journal of the Science of Food and Agriculture. https://doi.org/10.1002/jsfa.70060
Vancouver
Yang Z, Hao Y, Wang Z, Wang Z, Ye G, Gao F, et al. 5‐Heptadecylresorcinol ameliorates high‐fat diet induced non‐alcoholic fatty liver disease through modulating bile acid profile and suppressing inflammation. Journal of the Science of Food and Agriculture. 2025. doi:10.1002/jsfa.70060
BibTeX
@article{Yang2025,
author = {Yang, Zihui and Hao, Yiming and Wang, Ziyuan and Wang, Zongwei and Ye, Gaoqi and Gao, Fei and Wang, Jing and Liu, Jie},
title = {5‐Heptadecylresorcinol ameliorates high‐fat diet induced non‐alcoholic fatty liver disease through modulating bile acid profile and suppressing inflammation},
journal = {Journal of the Science of Food and Agriculture},
year = {2025},
doi = {10.1002/jsfa.70060}
}
EUVIMED